MYO1B (Myosin 1B) is a member of the myosin superfamily, a group of actin-based motor proteins involved in diverse cellular processes such as vesicle trafficking, membrane reorganization, and cytoskeletal dynamics. As an unconventional myosin, MYO1B lacks the long tail domain of conventional myosins but contains a motor domain for actin binding and ATP hydrolysis, followed by a lipid-binding TH1 domain that mediates interactions with cellular membranes. It plays critical roles in clathrin-mediated endocytosis, exocytosis, and maintaining cell polarity, particularly in epithelial and neuronal cells.
MYO1B antibodies are essential tools for studying the protein's expression, localization, and function. They are widely used in techniques like Western blotting, immunofluorescence, and immunoprecipitation to investigate MYO1B's involvement in intracellular transport, cell adhesion, and signaling pathways. Dysregulation of MYO1B has been linked to pathologies, including cancers (e.g., hepatocellular carcinoma, colorectal cancer) and neurological disorders, making these antibodies valuable for biomedical research. Commercial MYO1B antibodies are typically raised against specific epitopes, such as the N-terminal or C-terminal regions, and are available in polyclonal or monoclonal formats from various host species (e.g., rabbit, mouse). Validation data (e.g., knockout validation, species reactivity) are crucial to ensure specificity, as myosin family members share structural homology. Researchers utilize these antibodies to explore MYO1B's role in disease mechanisms and its potential as a therapeutic target.